Skip to main content
Smart Investors Daily
HU

NASDAQ · HURA

TuHURA Biosciences, Inc.

Healthcare · Biotechnology

$1.33

Down-$0.06 (-4.32%)

Updated Nov 17, 2026, 2:26 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
52.85M
P/E ratio
-0.79
Dividend yield
0.00%
52-week range
$0.41 – $3.43
Volume
1.33M
Avg. volume
236.59K

Price performance · HURA

HURA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

HURA closed at $1.33 after 21 trading sessions, down 25.28% for the selected period.

Last close
$1.33
Period change
-25.28%
Period low
$1.33
Period high
$2.18
Daily close
View OHLC price history
HURA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$1.415$1.4677$1.265$1.331.33M
Nov 13, 2026$1.51$1.5274$1.36$1.39371.86K
Nov 12, 2026$1.51$1.5699$1.37$1.45688.67K
Nov 11, 2026$1.605$1.6252$1.4841$1.52494.62K
Nov 10, 2026$1.675$1.675$1.50$1.51454.46K
Nov 9, 2026$1.70$1.7464$1.65$1.66415.89K
Nov 6, 2026$1.63$1.68$1.60$1.63403.07K
Nov 5, 2026$1.73$1.7996$1.56$1.61613.13K
Nov 4, 2026$1.67$1.7299$1.6301$1.72426.84K
Nov 3, 2026$1.77$1.8181$1.65$1.655570.35K
Nov 2, 2026$1.99$1.99$1.70$1.72646.26K
Oct 30, 2026$2.05$2.05$1.85$1.93524.07K
Oct 29, 2026$2.01$2.08$1.98$2.06298.08K
Oct 28, 2026$2.075$2.12$1.93$1.99569.4K
Oct 27, 2026$2.05$2.12$1.99$2.11401.22K
Oct 26, 2026$2.205$2.23$1.9301$2.04636.51K
Oct 23, 2026$2.07$2.185$2.05$2.181.01M
Oct 22, 2026$2.20$2.20$1.96$2.01609.26K
Oct 21, 2026$1.74$2.1099$1.71$2.0851.08M
Oct 20, 2026$1.77$1.81$1.75$1.7639.15K
Oct 19, 2026$1.75$1.96$1.74$1.78173.44K

Latest HURA news

The latest Smart Investors Daily articles mentioning HURA.

HURA research

Overview

Company profile and research snapshot.

Company profile

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
HURA recent ratings
DateFirmRatingTarget
Oct 27, 2026HC Wainwright & Co.Buy—
Aug 18, 2026CitizensMarket Outperform—
Apr 27, 2026CitizensMarket Outperform—
Feb 3, 2026HC Wainwright & Co.Buy—
Jan 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on Decembe

Yahoo · Nov 3, 2026

HURA: First Look at IFx-2.0 Deep-Seated Tumors

By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH NOTE Interim Readout for IFx-2.0 Phase Ib/IIa Open-Label Study TuHURA (NASDAQ:HURA) presented first data from its IFx-2.0 Phase Ib/IIa study in deep-seated Merkel cell carcinoma (MCC) patients while attending the European Society for Medical Oncology (ESMO) conference. TuHURA held a call in parallel with the event hosted by Rodman

Yahoo · Oct 26, 2026

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting. Speaking duri

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.